Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 60.80M | Perf Week | 9.04% |
| Market Cap | 483.93M | Forward P/E | - | EPS next Y | -2.94 | Insider Trans | 0.00% | Shs Float | 27.53M | Perf Month | -18.86% |
| Enterprise Value | 485.49M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 12.91% | Perf Quarter | -14.41% |
| Income | -157.33M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 6.64 | Perf Half Y | 9.49% |
| Sales | 0.00 | P/B | 2.46 | EPS next Y | -2.68% | ROA | -60.85% | Short Interest | 7.85M | Perf YTD | -15.32% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -81.87% | 52W High | 13.55 -41.77% | Perf Year | 139.04% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -71.42% | 52W Low | 2.78 184.29% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.59% 6.41% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 1.50% | Oper. Margin | 0.00% | ATR (14) | 0.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.15 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 51.74 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.15 | EPS Q/Q | 35.92% | SMA20 | 5.35% | Beta | 2.50 | Target Price | 25.00 |
| Payout | 0.00% | Debt/Eq | 0.17 | Sales Q/Q | - | SMA50 | -1.25% | Rel Volume | 0.41 | Prev Close | 7.96 |
| Employees | 129 | LT Debt/Eq | 0.11 | Earnings | Aug 11 | SMA200 | -3.95% | Avg Volume | 1.04M | Price | 7.89 |
| IPO Date | Feb 09, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.20% - | Net Debt/EBITDA | -0.01 | Volume | 431,396 | Change | -0.88% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-15-26 | Reiterated | HC Wainwright & Co. | Buy | $20 → $25 |
| Dec-16-25 | Reiterated | Wells Fargo | Overweight | |
| Dec-15-25 | Reiterated | UBS | ||
| Dec-15-25 | Reiterated | Morgan Stanley | Overweight | $25 |
| Dec-04-25 | Reiterated | Morgan Stanley | Overweight | $25 |
| Oct-27-25 | Reiterated | HC Wainwright & Co. | Buy | $10 → $20 |
| Aug-29-25 | Reiterated | HC Wainwright & Co. | Buy | $10 |
| May-27-25 | Upgrade | HC Wainwright & Co. | Neutral → Buy |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 2 | 2 | — | — | |
| Gross Profit | 0 | -2 | -2 | — | — | |
| Selling, General and Administrative Excl. Other | 36 | 30 | 12 | — | — | |
| Research and Development | 134 | 112 | 48 | — | — | |
| Other Operating Expense | 0 | -2 | 1 | — | — | |
| Operating Income | -170 | -143 | -62 | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | 15 | 2 | — | — | |
| Net Income Before Taxes | -161 | -127 | -60 | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -161 | -127 | -60 | — | — | |
| Net Income From Continuing Operations | -161 | -127 | -60 | — | — | |
| Net Income | -161 | -127 | -60 | — | — | |
| EPS (Recurring) | -3.64 | -3.33 | -0.00 | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.64 | -3.33 | -0.00 | — | — | |
| EPS (Diluted) | -3.64 | -3.33 | -0.00 | — | — | |
| EBITDA | -159 | -125 | -58 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | |
| Shares Outstanding | 44 | 38 | 674 | — | — | |
| Market Capitalization | 414 | 142 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SEIDENBERG BETH C | Director | Dec 18 '25 | Buy | 7.50 | 133,333 | 999,998 | 869,317 | Dec 22 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10% Owner | Dec 18 '25 | Buy | 7.50 | 133,333 | 999,998 | 869,317 | Dec 22 |
| Walker Karen Marie | Chief Technology Officer | Dec 15 '25 | Option Exercise | 4.83 | 23,998 | 115,910 | 46,634 | Dec 17 |
| Walker Karen Marie | Chief Technology Officer | Dec 15 '25 | Sale | 12.20 | 23,998 | 292,776 | 22,636 | Dec 17 |
| Walker Karen Marie | Chief Technology Officer | Jun 06 '24 | Option Exercise | 4.42 | 9,636 | 42,591 | 9,636 | Jun 10 |
| Jones Ryan Alexander | Chief Financial Officer | May 28 '24 | Option Exercise | 0.73 | 18,016 | 13,152 | 43,950 | May 29 |
| Vida Ventures, LLC | 10% Owner | Feb 12 '24 | Buy | 22.00 | 253,136 | 5,568,992 | 252,553 | Feb 14 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Feb 12 '24 | Buy | 22.00 | 450,000 | 9,900,000 | 3,163,868 | Feb 14 |
| GILEAD SCIENCES, INC. | 10% Owner | Feb 12 '24 | Buy | 22.00 | 910,000 | 20,020,000 | 4,126,119 | Feb 13 |
| Northpond Ventures III GP, LLC | other: Former 10% Owner | Feb 12 '24 | Buy | 22.00 | 450,000 | 9,900,000 | 450,000 | Feb 12 |